Human bone marrow cells derived from multiple sclerosis (MS) and control patients were screened for a number of virus antigens by the fluorescent antibody technique using monoclonal antibodies. The results showed that antigens of the paramyxovirus, simian virus 5, were present in about 60~ of MS and 25% of control bone marrows. About 25 % of the MS and 50 % of control bone marrows were found to contain nucleoprotein antigen of the human parainfluenza types 1 and 3. These experiments demonstrated that paramyxoviruses can persist in human tissues possibly in a defective or repressed state.
INTRODUCTION
There have been a number of reports of the isolation of transmissible agents from tissues derived from patients with multiple sclerosis (MS) (for review, see Cook & Dowling, 1980) but none of these has been substantiated by later investigators. Thus, the report by Mitchell et al. (1978) of a transmissible cytopathogenic agent found in bone marrows of MS patients and isolated after multiple tissue culture passage was not confirmed in later studies by other workers (Huddlestone et al., 1979) . Indeed, the picture was further complicated by the discovery of mycoplasma contamination in some of the original isolates (Mitchell et al., 1979) .
Notwithstanding these apparently negative observations we have demonstrated, on at least five separate occasions over the subsequent 3 years, that agents transmitting a cytopathic effect (c.p.e.) could be isolated from MS-derived bone marrows in the apparent absence of mycoplasma contamination. Neutralization and fluorescent antibody techniques have clearly shown that the isolates were related to the paramyxovirus simian virus 5 (SV5) (Goswami & Russell, 1982; Goswami et al., 1984) . One of these original isolates (designated RQ) was examined in greater detail along with the prototype SV5 strain using immunoprecipitation techniques and both were shown to be closely related to human parainfluenza virus type 2 (PF-2) but not to type 1 (PF-1) or type 3 (PF-3), the major difference being in the haemagglutinin-neuraminidase (HN) component (Goswami & Russell, 1982) . To study these antigenic relationships in more detail and to provide more highly specific reagents, monoclonal antibodies against both SV5 and PF-3 viruses have been prepared (Goswami & Russell, 1983) . Two different epitopes have been detected on the SV5 HN polypeptide: one (HN-I) is entirely specific to SV5 and the other (HN-2) cross-reacts with the PF-2 HN polypeptide in fluorescent antibody and radioimmunoassay tests. Both of these epitopes seem to be neutralization epitopes for SV5 but not for PF-2. One epitope (NP-1) on the SV5 nucleoprotein was demonstrated and this cross-reacted in immunoprecipitation and fluorescent antibody tests with PF-2-infected cells. It is pertinent to note that SV5 has been shown to be a contaminant of some primary monkey kidney cell cultures and has also been detected in some tissue culture cell lines (Zakstelskaya et al., 1976) and therefore some doubt arises as to whether the isolates described above had arisen as a result of adventitious contamination on tissue culture passage or indeed reflected the presence of SV5 virus in the original bone marrows. We have approached this question by utilizing the monoclonal antibodies as specific probes to examine directly bone marrows derived from MS and control patients using fluorescent antibody techniques. The results, described here, show unequivocally that about 60~o of MS and about 25~ of control bone marrows examined contain SV5 antigens. Moreover, since spread and passage of the antigens could be demonstrated it can be concluded that some bone marrow cells harbour the SV5 paramyxovirus. These studies have also shown that about 25 ~ of MS and about 50 ~ of control bone marrows contain nucleoprotein antigen of the PF-I/PF-3 viruses although in this case no spread or passage of antigens could be demonstrated.
METHODS
Patients. Bone marrow aspirates were obtained from MS patients in North London under the clinical care of one of us (L.S.L.). These patients were assessed using the internationally accepted criteria for diagnosis. The bone marrows from non-MS patients were derived via routine diagnostic laboratories and came from patients suffering from a variety of conditions requiring bone marrow analysis. They were not therefore matched in any way with the MS patients. Some details of the patients are described in Table 1 .
Bone marrow co-cultivation. Bone marrow samples were aspirated into preservative-free heparin saline (5 u/ml) and transferred into culture within 2 to 3 h of coUection. One vol. of the bone marrow cells (1 x 106 per ml) was mixed with 2 vol. of Vero cells (105 per ml) and then placed directly onto multispot microscope slides (Hendley; PTFE) in H21 medium with 10~ foetal calf serum and incubated at 37 °C in a humidified COz incubator for 15 to 18 h. Another duplicate sample was transferred with a Veto cell suspension to wells of a plastic tissue culture plate (Linbro) and incubated similarly. A third sample was mixed with the suspension of Vero cells but in the presence of polyethylene glycol (PEG 4000; Serva, Heidelberg, F.R.G.) (Russell et al., 1981) to promote fusion of the bone marrow and tissue culture cells. After fusion the cells were placed on the multispot slides and in the plastic tissue culture wells as described above. The cultures on the multispot slides were utilized for th~ fluorescent antibody studies whereas the companion cultures in wells of the tissue culture trays provided material for further passage.
Fluorescent antibody techniques. After incubation, the bone marrow/Vero cell cultures on microscope slides were fixed in saline containing 5 ~ formaldehyde and 2 ~ sucrose for 5 min on ice and then washed gently in phosphatebuffered saline (PBS). Five-gl drops of 1/100 dilutions of monoclonal antibodies in PBS were then added as appropriate to the individual wells of the slide and incubated at 37 °C in a humidifier chamber for 30 min. The slides were again washed three times in PBS and 5-gl drops of an optimal dilution of fluorescein-conjugated anti-mouse globulin (Nordic), previously adsorbed with human bone marrow cells were added and incubated as above. The slides were washed again, mounted and analysed by fluorescence microscopy (Russell et al., 1981) .
Monoelonal antibodies. Monoclonal antibodies against SV5 (RQ isolate) and PF-3 (Goswami & Russell, 1983) , measles glycoprotein ), adenovirus hexon (Russell et al., 1981) and influenza virus nucleoprotein (M. A. Muggeridge, unpublished results) were used as dilutions of ascitic fluids. In some later experiments IgG was obtained by Protein A-agarose affinity chromatography (Goswami & Russell, 1983 ) from ascitic fluid and used at comparable dilations.
Serology. Sera from patients were collected and their abilities to neutralize SV5 (RQ) were assessed using a microtitre plate assay as previously described . The presence of antibodies against SV5/PF-2 group of viruses in the sera and bone marrow aspirates was also analysed by measuring their ability to react with SV5 (RQ)-infected Vero cells using fluorescein conjugated anti-human globulin. Vero cells growing on the multispot slides were infected with SV5 (RQ) virus and after 42 h incubation (when c.p.e, was just becoming apparent) they were fixed, washed, incubated with dilutions of sera or cell-free bone marrow aspirates, washed and stained with the fluorescein-conjugated anti-human globulin (Nordic) as described above.
RESULTS

Analyses of bone marrows by fluorescence
A total of 24 bone marrows were examined by the fluorescent antibody techniques using monoclonal antibodies against SV5, PF-3, measles, influenza and adenovirus antigens. As described in Methods the bone marrow aspirates were mixed with a suspension of Vero cells (with and without P E G 4000) cultured on microspot slides and examined after incubation. This procedure allowed the bone marrow cells to attach and interact with the tissue culture cells and provided a much more satisfactory environment than simply culturing the bone marrow cells on their own. (Indeed, preliminary experiments using conventional bone marrow smears did not provide a useful basis for adequate washing and retention of cells.) The origins of the different bone marrow samples were not disclosed until after the fluorescent surveys were completed. The results in Table 1 show 8/13 of the MS bone marrows and 3/11 of the non-MS bone marrows elaborated SV5 antigens as detected with the two SV5 monoclonal antibodies (the SV5 HN-2 epitope could also be detected in the SV5-positive bone marrows). All the other monoclonal antibodies tested gave negative results in these tests, with the exception of the monoclonal antibody against the nucleoprotein antigen of PF-3 (which will not discriminate between PF-3 and PF-1). This monoclonal antibody gave positive reactions with 3/13 of MS and 5/11 of the control bone marrows. It should be noted that no reaction could be detected with monoclonal antibodies against the PF-3 glycoproteins. It also became apparent that the presence of P E G 4000 in the initial cultivation did not seem to influence the results obtained although there was some indication that spread of the antigens was promoted in its presence (see below). It is interesting that in this series of tests a bone marrow sample from patient 13 (RQ who provided one of the well-characterized isolates) also gave a strong positive result. Fig. 1 illustrates the nature of the antigens detected and it can be seen that the fluorescence initially appeared in isolated cells of variable size (Fig. 1 a) , very probably of bone marrow origin, and as the incubation proceeded the carrier Vero cells also elaborated antigens (Fig. 1 b) . The spread of antigen-producing cells could be detected over a period of 5 to 7 days and was accompanied by local degeneration of cells (Fig. 1 c) . However, it was notable that fluorescence did not become generalized and remained focal in origin.
In the three cases where non-MS-derived bone marrows exhibited fluorescence one did not show any propensity to spread even on prolonged culture and the other gave limited evidence of spreading to neighb'ouring Vero cells (Fig. 2a) . All the bone marrows giving positive results with the PF-3 monoclonal antibody showed fluorescence only on isolated cells (Fig. 2b) , apparently only in the bone marrow cells and did not show any ability to promote spread of the antigen on incubation, even in the presence of PEG 4000. No fluorescence could be detected in uninoculated Vero cells using any of the monoclonal antibodies. It was also noted that varying degrees of c.p.e, were obtained in the initial cultures of bone marrows with the Vero cells (in the absence of PEG 4000) but the c.p.e, was not necessarily correlated with the presence of paramyxovirus antigens as detected by fluorescence.
Passage of primary cultures
Samples of supernatant fluids from those primary cultures showing the presence of fluorescent antigens were transferred to fresh Vero cell monolayers (on multispot microscope slides and tissue culture plates) and analysed by the fluorescence techniques. In the case of the RQ bone marrow, positive focal reactions were still evident up to the third passage (i.e. 20 days after the primary cultivation) (Fig. 1 d) . Three of the other positive MS bone marrows continued to give positive fluorescence with the SV5 monoclonal antibodies up to the second passage. Further passage of the supernates did not, however, yield cells with positive fluorescence, indicating that the incumbent virus was not capable of further propagation under these conditions. It did not prove possible to passage via supernatant fluids the fluorescent antigen seen with three non-MS bone marrows or indeed the fluorescent antigens detected using the monoclonal antibody against the PF-3 nucleoprotein.
However, much better results were obtained when cells were disrupted either by sonication or by freezing and thawing and the cell extract transferred with the supernates. When this procedure was followed, the RQ bone marrow has shown continuous passage of the ability to produce fluorescence (at present until the sixth passage). It has not yet been possible to achieve a similar result with the control bone marrows (although only two have been examined in this way). Table 1 also shows that neutralizing antibody to SV5 was present in 8/13 of the MS patients as compared to 1/11 of the non-MS patients in this series of tests. The presence of neutralizing antibody correlated very well with the ability to detect SV5 antigen in bone marrow, there being only two non-MS patients who apparently showed a positive reaction in bone marrows with no detectable neutralizing antibodies. The antibody status of the patients against the SV5/PF-2 members of the paramyxovirus genus was also examined by testing the abilities of the sera (and dilutions thereof) to react with SV5-infected Vero ceils using the appropriate fluorescent conjugate (Fig. 2 c) . Almost all of the sera showed significant reactions in this test, no doubt reflecting the ubiquity of PF-2 human infection. The same test was used to assess the antibody content of the bone marrow samples and it was apparent once again that most of the samples contained antibody of this nature. Since the aspirates contained variable amounts of blood it was not clear without further examination whether the antibody present reflected bone marrow-derived antibodies or merely contamination.
Antibody status of patients
DISCUSSION
It is evident from these experiments that a significant proportion of human bone marrows contain antigens of paramyxovirus origin. Since all three monoclonal antibodies against different SV5 epitopes react (including one specific to SV5 and not cross-reacting with PF-2) and there is evidence of the ability to passage the production of these antigens to co-cultivated tissue culture cells, it can be concluded that the bone marrow cells harbour the SV5 virus. However, the fact that propagation of the virus was achieved initially only by utilizing cell extracts suggests that the virus is in a defective or repressed state. Nevertheless, the results do vindicate the initial observations (Mitchell et al., 1978) of a transmissible agent from bone marrows and rule out the possibility that the isolations of SV5 virus were adventitiously derived as contaminants during tissue culture passage.
In turn, this finding poses the question of the significance of a 'simian' virus in association with human tissue and this point has been addressed in a parallel study analysing the antigenic and electrophoretic properties of the bone marrow isolates and also the nature of the neutralizing antibodies found in humans particularly making use of the specific SV5 monoclonal antibody . These experiments showed that about 20 ~ of the human sera examined contained SV5-neutralizing antibodies and, by means of a specific blocking test involving the SV5 monoclonal antibody, it was demonstrated that this was not the result of crossreacting PF-2 antibodies. SV5 virus can therefore be regarded as a paramyxovirus capable of infecting humans and since SV5 has also been associated with respiratory and neurological disease in dogs (Cornwell et al., 1976; Evermann et al., 1980) it seems plausible to postulate a fairly widespread dissemination of the virus in a variety of species. No difference was found in the parallel studies on the frequency or level of SV5 antibodies in the MS and control patients' sera examined . In contrast, in the study described here the frequency of antibody detection was significantly greater in the MS patients' sera but since smaller numbers were involved and no attempt was made to match the non-MS sera, it does not seem likely that this will be of any diagnostic significance.
However, the significance of the findings in terms of the aetiology of MS is still far from clear. Thus, the presence or absence of the virus does not directly correlate with the presence of the disease and the serology does not indicate any direct association with the disease. Nevertheless, it is not obvious why the MS bone marrows should apparently show the ability to passage the virus more efficiently than the non-MS bone marrow cells. It is tempting to speculate that this may be an indirect effect resulting from antibody impairment in the MS patients. It seems plausible to suggest that antibody-mediated antigenic modulation ) could play a role in bone marrows in selecting a virus population which can no longer function as effectively extraceUularly as it can intracellularly, i.e. a persistent paramyxovirus infection is normally well controlled in an individual with a normal immune response. However, if there is some aberration on the immune system, then loss of control of the persistent infection might resuit. In the case of the PF-3 (PF-1) persistent infection noted in this study it could be postulated that since only nucleoprotein antigen appears to be expressed then complete suppression of the gene products required for extracellular expression has been achieved.
Much further work is obviously required before the significance of these findings can be adequately assessed. Thus, the nature of the bone marrow cells elaborating the antigens and the quality of the antibodies found both in the bone marrow and in sera may determine the nature of the persistence and its possible relationship to neurological disease. We have also recently shown that some of these MS patients possess high levels of the SV5/PF-2 antibodies in their cerebrospinal fluid, and in the light of these findings we are currently exploring the possibility that the SV5 antigens contain an epitope that cross-reacts with some critical component related to x,~lination mj .......... One of us (K.K~A.G.) is grateful for personal salary support from the Multiple Sclerosis Society.
